NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 56

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. PC 02240 315375

Licensee	In accordance with the letters dated **January 11, 2006, and April 13, 2006,**
1. St. Joseph Health Center	3. License number 24-02704-01 is amended in its entirety to read as follows:
2. 1000 Carondelet Drive Kansas City, MO 64114	4. Expiration date December 31, 2015
	5. Docket No. 030-02310 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Iodine-125 as permitted by 10 CFR 35.1000	**D. Liquid as Iotrex™**	**D. Five curies**
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged kits	E. As needed

9. Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic or therapy procedure permitted by 10 CFR 35.300.

D. For use in the Proxima Therapeutics' GliaSite® Radiotherapy System for medical use permitted by 10 CFR 35.1000.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 24-02704-01

Docket or Reference Number 030-02310

Amendment No. 56

E. In vitro studies.

CONDITIONS

10. Location of Use: 1000 Carondelet Drive, Kansas City, Missouri.

11. Radiation Safety Officer: Patrick M. O'Toole, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. Licensed material listed in Item 9 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated.

Authorized Users

James P. Anthony, M.D.	10 CFR 35.100, 35.200, and 35.300.
Kenneth L. Koontz, M.D.	10 CFR 35.100, 35.200, and 35.300.
Patrick M. O'Toole, M.D.	10 CFR 35.100, 35.200, and 35.300.
Ronald R. Weis, M.D.	10 CFR 35.100, 35.200, and 35.300.
Charles W. Horner, M.D.	10 CFR 35.100, 35.200, and 35.300.
David J. Burkart, M.D.	10 CFR 35.100, 35.200, and 35.300.
J. J. Goetz, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Bruce Hoskins, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**
Lori A. Lindstrom, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 24-02704-01

Docket or Reference Number 030-02310

Amendment No. 56

James R. Coster, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**
Arthur J. Elman, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**
Robyn M. Hart, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**
Kenon S. Qamar, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**
Daniel Keleti, M.D.	**Iodine-125 in the Proxima Therapeutics' GliaSite® Radiotherapy System.**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

14. **In addition to the possession limits listed, the licensee shall further restrict the possession of licensed material to quantities below the minimum limits specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.**

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 24-02704-01

Docket or Reference Number 030-02310

Amendment No. 56

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. **This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26.** The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application June 6, 2005 (excluding specific materials listed for inclusion in 10 CFR 35.300, procedures for written directives);

B. Letters dated June 13, 2005, **January 11, 2006, and April 1[illegible], 2006.**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 11 2006

By Colleen Carol Casey

Colleen Carol Casey
Materials Licensing Branch
Region III